According to Marcus Snow, MD, assistant professor of internal medicine in the division of rheumatology, University of Nebraska Medical Center, some of the most critical developments in the biosimilars space during 2017 were the result of payer decisions.
According to Marcus Snow, MD, assistant professor of internal medicine in the division of rheumatology, University of Nebraska Medical Center, some of the most critical developments in the biosimilars space during 2017 were the result of payer decisions.
CMS’ move to assign biosimilars unique reimbursement codes is a “big step,” according to Snow, but he also points to what he calls “a smaller development that signals that biosimilars may take longer than expected to have a market share"—the agreement between UnitedHealthcare and Janssen that resulted in the brand-name Remicade being made the payer’s preferred infliximab therapy. “While [the move] is not unexpected from a business sense, it did signal to all in rheumatology practice that biosimilars in the [United States] may have much slower uptake than many thought. It will be interesting to see how other payers adjust to competition in the biologic marketplace.”
Slow market entry and sluggish market uptake are cause for concern for Snow. “Amjevita (adalimumab-atto) will not be available until 2023 [in the United States] due to a legal settlement. It is FDA-approved, and many hoped it would be available in the near future but, it will not be available here for quite some time,” and even those therapies that have launched have struggled in the marketplace: “Inflectra has only reported about 2% of the market share despite being FDA approved and commercially available…which is maybe a bit surprising, but this demonstrates more of a formulary issue than lack of use or desire to use biosimilar infliximab by the treating rheumatologist.” Snow added that, “While the choice in treatment ideally would come out of a discussion between the treating provider and the patient, the decision regarding drug availability to the patient is made by the [pharmacy benefit manager] and the insurance company, not the healthcare provider.”
In 2018, Snow hopes to see a market entry for the first FDA-approved etanercept biosimilar, Erelzi, which he says “would probably be the most interesting biosimilar,” as it “would be the first available subcutaneous [anti—tumor necrosis factor] biosimilar in the rheumatology world, especially with the delay of Amjevita’s US debut…the availability of both drugs has been delayed due to legal challenges, but Erelzi is reported to be close to becoming available,” said Snow.
As rheumatologists wait for greater biosimilar availability, Snow reports that he sees increasing awareness of biosimilar therapies among his peers: “There is increased familiarity with biosimilars among rheumatologists, and this will keep growing in 2018. When [biosimilars] truly become available to the provider, trust in the biosimilars will grow quickly [as] the provider becomes more familiar with the drug.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.